导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.50% | 1243/4773 |
| 近一周 | -1.11% | 1696/5465 |
| 近一月 | -1.57% | 1197/5421 |
| 近一季 | 0.05% | 993/5231 |
| 近半年 | 3.49% | 925/4920 |
| 近一年 | 8.04% | 1389/4394 |
| 近两年 | 45.87% | 1639/2954 |
| 近三年 | 30.15% | 1083/2253 |
| 成立以来 | 57.07% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.07% 3022/4961 |
9.76% 2466/5312 |
- - |
- - |
| 2025 | 15.00% 2577/4813 |
0.18% 1959/3635 |
1.77% 2155/4076 |
11.62% 3146/4524 |
1.06% 1564/4813 |
| 2024 | 15.81% 879/3463 |
3.05% 631/2808 |
-0.03% 670/3014 |
13.67% 2137/3129 |
-1.10% 1588/3463 |
| 2023 | -11.02% 1363/2656 |
1.34% 1591/2280 |
-5.06% 1362/2385 |
-0.93% 467/2515 |
-6.65% 1858/2655 |
| 2022 | -17.38% 584/2207 |
-12.47% 620/1919 |
5.97% 799/2016 |
-12.53% 723/2113 |
1.83% 1124/2208 |
| 2021 | -5.32% 974/1822 |
-2.62% 680/1255 |
4.66% 859/1330 |
-5.96% 884/1466 |
-1.21% 1332/1822 |
| 2020 | 43.19% 252/1250 |
-8.92% 640/1028 |
16.51% 433/1067 |
18.16% 86/1164 |
14.21% 291/1184 |
| 2019 | 20.72% 660/1092 |
13.21% 699/754 |
-0.62% 278/804 |
0.25% 541/850 |
7.04% 498/918 |
| 2018 | -19.62% 173/834 |
- - |
- - |
- - |
-10.32% 190/691 |
| 2017 | 17.74% 220/714 |
- - |
- - |
- - |
- - |
| 2016 | 1.14% 96/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国泰沪深300指数增强C VS. 长安沪深300非周期A(740101) |